



TML: CS: 2018-19;

8th February, 2018

The General Manager
Bombay Stock Exchange Ltd.
P. J Towers, Dalal Street,
Mumbai- 400 001.

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla
Complex, Bandra – East,
Mumbai- 400 051.

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Meeting Commencement time : 03:30 P.M
Meeting Conclusion Time : 04:45 P.M

The Board of Directors at its meeting held today, approved the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2018.

A copy of Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2018 together with Limited Review Report is enclosed for your perusal.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record and acknowledge receipt.

Thanking you,
Yours faithfully,

For **THEMIS MEDICARE LIMITED**



SANGAMESHWAR IYER
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India
Tel. : 91-22-6760 7080 • **Fax :** 91-22-6760 7070 / 2874 6621
Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.
CIN No.: L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off. :** 0260 2431447 / 2430219
• **E-mail :** themis@themismedicare.com • **Website :** www.themismedicare.com



Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

Limited Review Report on Quarterly Unaudited Consolidated Financial Results of Themis Medicare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

***To The Board of Directors of
Themis Medicare Limited.***

We have reviewed the accompanying statement of unaudited Consolidated financial results ('the Statement') of Themis Medicare Limited ('the Company') for the quarter ended 30th June, 2018, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31st March, 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 8th August, 2018. Our responsibility is to issue a report on this statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Raju P. Sardar
B.Com., F.C.A.


R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

The comparative unaudited financial results of the Company for the quarter ended 30th June, 2017 included in this Statement had been reviewed by the predecessor auditors who had expressed an unmodified conclusion thereon as per their reports dated 4th September, 2017 and which have been furnished to us by the Management and have been relied upon by us for the purpose of our review of the statement. Our conclusion is not modified in respect of this matter.

R. P. Sardar & Co.
Chartered Accountants
Registration No. 109273W

Raju P. Sardar
Proprietor
Membership No. 037845



Place: Mumbai
Date: 8th August, 2018

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.



Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter ended 30th June 2018.

(Amount in INR Lakhs)

	Particulars	STANDALONE			
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Previous Year ended
		30/06/2018	31/03/2018	30/06/2017	31/03/2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	5,045.71	5,220.49	4,744.00	21,170.67
2	Other Income	30.31	75.98	27.43	303.53
3	Total Income (1 + 2)	5,076.02	5,296.47	4,771.43	21,474.20
4	Expenses :				
	(a) Cost of materials consumed	812.79	1,331.22	1,172.29	5,326.79
	(b) Purchases of stock-in-trade	493.99	229.65	666.65	1,988.47
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	404.39	(84.79)	(298.09)	(148.89)
	(d) Excise Duty	-	-	220.34	220.34
	(e) Employee benefits expense	1,216.62	1,117.14	1,065.34	4,461.76
	(f) Finance Costs	282.03	280.95	299.70	1,186.68
	(g) Depreciation and amortisation expense	193.73	215.81	170.64	740.93
	(h) Other expenses	1,695.84	1,591.00	1,857.10	6,758.45
	Total expenses	5,099.39	4,680.98	5,153.97	20,534.53
5	Profit / (Loss) before exceptional items and tax (3 - 4)	(23.37)	615.49	(382.54)	939.67
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5 - 6)	(23.37)	615.49	(382.54)	939.67
8	Tax expense :				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax	(30.71)	80.54	(13.55)	10.18
9	Profit / (Loss) for the period (7 - 8)	7.34	534.95	(368.99)	929.49
10	Other Comprehensive Income :				
	(a i) Items that will not be reclassified to Profit & Loss	(2.10)	(24.88)	0.65	(22.87)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	0.73	8.61	(0.06)	7.92
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-
11	Total Comprehensive Income for the period (9 + 10)	5.97	518.68	(368.40)	914.54
12	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	918.09	918.09	904.44	918.09
13	Other Equity (Excluding Revaluation Reserve)				11,107.64
14	Earnings per share :				
	(a) Basic	0.08	5.83	(4.07)	10.12
	(b) Diluted	0.08	5.82	(3.97)	10.10

NOTES :

- 1) The Unaudited financial statements for the quarter ended June 30th 2018 have been reviewed by the Audit & Risk Management Committee and approved by the Board of Directors at its meeting held on 08.08.2018. The Statutory Auditors have expressed an unqualified opinion. The information presented above is extracted from Unaudited standalone financial statements. The financial statements are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 2) The Company has only one segment namely pharmaceuticals and hence, no separate segmentwise disclosure has been made.
- 3) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4) The Government of India introduced the Goods and Services Tax (GST) with effect from 1st July 2017, Consequently revenue from operations for the quarter ended 30th June 2018 is net of GST, However, revenue for the quarter ended 30th June 2017 is inclusive of excise duty.
- 5) The figures of quarter ended March 31, 2018 are the balancing figures between audited figures in respect of full financial year and published year-to-date figures upto the third quarter of the year ended March 31, 2018.
- 6) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.


For R. P. Sardar & Co.
Chartered Accountants



Raju P. Sardar
Proprietor

Place : Mumbai
Date : 08 / 08 / 2018

By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)
(DIN No. 00033353)

